NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Creative Medical Technology Holdings, Inc. CELZ
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$6,000
▼ 45.5% vs FY2024
EPS · FY25
$-2.52
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-86.5%
Net margin · FY25
-99916.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 6,000.00
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 99917 cents on every revenue dollar this year.
Per share
USD -2.52
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-86.5%
Return on equity, FY2025
ROE
Operating margin-102380.2%
Net margin-99916.8%
Return on assets-82.8%
Each USD of equity lost 87 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -7.2M
Share of profit-0.0%
Consecutive raises—
Growth
−48.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−59.2%
−48.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.8M
total assets, end of FY2025
Total assetsUSD 7.8M
EquityUSD 7.5M
CashUSD 7.2M
Current ratio25.97×
Equity funds 96% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.52
−3.71
−3.76
−0.93
5.61
−62.69
−0.82
−3.50
−0.03
−0.01
0.00
0.00
0.00
0.00
0.00
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−86.5
−65.8
−40.3
−77.8
·
·
·
·
·
·
·
·
·
·
·
·
Shares out B
0.00
0.00
0.00
0.00
0.01
0.00
0.02
0.01
0.11
0.11
0.03
0.02
0.02
0.02
0.02
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed